Indefinite Delivery Contract SPE2DX16D2920

The federal contract IDV awarded to Amerisourcebergen Drug Corp is a single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical, valued at up to $999,999,999.00 and running through December 31, 2025. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions worldwide. The contract encompasses a diverse array of critical medical commodities, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains such as cardiovascular health, diabetes management, mental health treatments, pain management, infectious disease prevention, and general medical care. Additionally, Amerisourcebergen holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs enable the efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries through a streamlined, comprehensive contracting mechanism.

The contract awards to Amerisourcebergen and its parent company, Cencora, Inc., demonstrate the companies' extensive capabilities in pharmaceutical distribution and medical supply chain management. As a major supplier to federal healthcare programs, particularly within the Department of Defense and Department of Veterans Affairs, Amerisourcebergen and Cencora play a critical role in ensuring the availability of vital medical commodities to support the medical readiness and treatment of U.S. military members, veterans, and other federal healthcare recipients. The contract awards were made through full and open competition without any set-aside requirements, reflecting the companies' strong competitive position in the pharmaceutical distribution market.